Capabilities

Acquisition of Pharmion Corporation

Celgene Corporation
2007 - 2008

Our attorneys represented Celgene Corporation, a multinational biopharmaceutical company, in connection with its $2.9 billion acquisition of Pharmion Corporation. Although both Celgene and Pharmion marketed medicines used in the treatment of certain cancers of the blood, the team was able to demonstrate that the drugs were not in head to head competition through an in-depth exploration of the drugs' mechanisms of action and their therapeutic usage. In the US, the FTC cleared the transaction without a Second Request under the Hart-Scott-Rodino Act and in Germany, the Federal Cartel Office approved the transaction without requiring a Phase 2 investigation.

Email Disclaimer